Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics (Nasdaq: NTLA) announced on April 1, 2026 it granted inducement awards to 13 new employees under its amended 2024 Inducement Plan.

Rhea-AI Summary

Intellia Therapeutics (Nasdaq: NTLA) announced on April 1, 2026 it granted inducement awards to 13 new employees under its amended 2024 Inducement Plan. The awards comprised 67,150 RSUs vesting one-third annually over three years and were approved by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).

All equity vesting is conditioned on continued service through vesting dates; awards were granted outside stockholder-approved plans pursuant to the inducement plan adopted by the board in June 2024.

Argus Apr 6 session

+1.29% close to close Open Argus

Details

News Market Reaction – NTLA

On Apr 6, the first trading day after this news, NTLA closed 1.29% above the previous close.

Data tracked by StockTitan Argus for the Apr 6 session.

Key Figures

Inducement RSUs granted: 67,150 shares New employees: 13 Vesting schedule: One-third annually +4 more

Inducement RSUs granted

67,150 shares

Time-based RSUs under 2024 Inducement Plan

New employees

13

Employees receiving inducement grants on April 1, 2026

Vesting schedule

One-third annually

RSUs vest over three years, time-based

Vesting period

3 years

Time-based RSU vesting period

Grant date

April 1, 2026

Date inducement RSUs were awarded

Plan adoption

June 2024

Initial adoption of 2024 Inducement Plan by board

Listing rule

Nasdaq 5635(c)(4)

Governs inducement equity grants for new employees

Historical Context

5 past events · Latest: Mar 06

5 events

1. Mar 06

   Inducement grants

   24h Move

   +3.4%

   RSU inducement awards to six new employees under 2024 Inducement Plan.

2. Mar 03

   Clinical data update

   24h Move

   -11.9%

   Longer-term HAE data for lonvo-z showed durable attack reduction and control.

3. Mar 02

   Clinical hold lifted

   24h Move

   +12.1%

   FDA lifted clinical hold on MAGNITUDE Phase 3 ATTR-CM trial with added safeguards.

4. Feb 26

   Earnings and updates

   24h Move

   +6.4%

   Q4/FY25 results with cash of $605.1M and clear HAELO, BLA and MAGNITUDE plans.

5. Feb 24

   Investor conferences

   24h Move

   +3.2%

   Participation in three early March investor conferences with webcast access.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

crisper gene editing, restricted stock units, nasdaq listing rule 5635(c)(4)

3 terms

crisper gene editing medical

"focused on revolutionizing medicine leveraging CRISPR gene editing and other core"

A laboratory technique that acts like precise molecular scissors to cut, remove or change specific parts of DNA inside living cells; it lets scientists alter genes with much greater accuracy than older methods. Investors watch it because successful gene edits can lead to new medicines, agricultural products or diagnostics, while also carrying high research costs, long regulatory reviews, patent disputes and binary clinical trial outcomes that can sharply change a company’s value.

restricted stock units financial

"The inducement grants consisted of time-based restricted stock units (“RSUs”)"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on April 1, 2026, it awarded inducement grants to 13 new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment.

The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 67,150 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.

All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, as amended, which was initially adopted by the board of directors in June 2024. These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).

About Intellia Therapeutics

Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.

Contact:

Jason Fredette
Vice President, Investor Relations and Corporate Communications
jason.fredette@intelliatx.com

This press release was published by a CLEAR® Verified individual.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Intellia (NTLA) grant on April 1, 2026 under the 2024 Inducement Plan?

Intellia granted 67,150 restricted stock units to 13 new employees as inducement awards. According to the company, the RSUs vest one-third annually over three years and were approved under Nasdaq Listing Rule 5635(c)(4).

How do the NTLA inducement RSUs vest and what are the service conditions?

The RSUs vest in three equal annual installments, with one-third vesting each year. According to the company, vesting requires continued service as an employee or service provider through the applicable vesting dates.

Were the NTLA inducement awards granted under existing stockholder-approved plans?

No, the awards were granted outside stockholder-approved plans under Intellia's amended 2024 Inducement Plan. According to the company, the plan was initially adopted by the board in June 2024 and amended thereafter.

Why did Intellia (NTLA) approve inducement grants under Nasdaq Listing Rule 5635(c)(4)?

The grants were approved as a material inducement to employment for new hires. According to the company, the compensation committee approved the awards in accordance with Nasdaq Listing Rule 5635(c)(4).

How many employees received inducement awards from Intellia (NTLA) on April 1, 2026?

Thirteen new employees received inducement grants under the 2024 Inducement Plan. According to the company, the aggregate award size was 67,150 RSUs and vesting is service-based.